Ignacio Casarini

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Shun Lu, Terufumi Kato, Xiaorong Dong et al. · New England Journal of Medicine · 2024 · 232 citations

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress

Shun Lü, Ignacio Casarini, Terufumi Kato et al. · Clinical Lung Cancer · 2021 · 63 citations

Definitive Chemoradiation, Medicine, Osimertinib Maintenance +9

121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy

Nir Peled, Julien Mazières, Dariusz M. Kowalski et al. · Immuno-Oncology Technology · 2023 · 12 citations · Full text